← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Triple immunostaining demonstrates the possible existence of segregated-nucleus-containing atypical monocytes in human primary myelofibrosis bone marrow: a case report. (2024/10/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treatment Strategies Used in Treating Myelofibrosis: State of the Art. (2024/10/30) ♡
• Myeloproliferative Neoplasm-like Mutations of Calreticulin Induce Phenotypes Associated with Calreticulin Dysfunction in C. elegans. (2024/10/29) ♡
• RUNX1::CBFA2T2 rearranged acute myeloid leukemia transformed from JAK2 V617F mutated primary myelofibrosis. (2024/10/29) ♡
• Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study. (2024/10/28) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. (2024/10/25) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Anemia response in myelofibrosis revisited. (2024/10/24) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. FDA greenlights momelotinib (Ojjaara) as the exclusive treatment for myelofibrosis patients battling anemia. (2024/10/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology. (2024/10/21) ♡
• Burden of Symptoms and Symptom Experience of Filipino Patients with Myeloproliferative Neoplasm: A Qualitative Phenomenological Approach. (2024/10/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review. (2024/10/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Thrombotic, Cardiovascular, and Microvascular Complications of Myeloproliferative Neoplasms and Clonal Hematopoiesis (CHIP): A Narrative Review. (2024/10/12) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. An unusual case report of myelofibrosis following treatment for acute promyelocytic leukemia with myeloid sarcoma as the initial manifestation. (2024/10/09) ♡
• [Clinical Characteristics and Survival Analysis of Single Center Adult Chronic Myeloid Leukemia in Chronic Phase]. (2024/10/01) ♡
• [Analysis of Incidence Rate, Risk Factors and Prognosis of Pulmonary Hypertension in Ph(-)MPNs Patients]. (2024/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The role of corticosteroids in the current treatment paradigm for myelofibrosis. (2024/10/01) ♡
• Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis. (2024/09/25) ♡
• Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen-Single-Center Analysis. (2024/09/25) ♡
• Efficacy of nebulized GM-CSF inhalation in preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation: A retrospective study. (2024/09/12) ♡
• Magnetic Resonance Imaging Guided Radiation Therapy for Splenomegaly: Clinical Experiences and Technical Tips. (2024/08/28) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Vitamin B12 Deficiency Manifesting As Pancytopenia, Lymphadenopathy, and Fever: A Clinical Mimic of Hematologic Malignancies. (2024/07/16) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Shaping hematopoietic cell ecosystems through galectin-glycan interactions. (2024/07/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Persistent Sweet syndrome post-hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis. (2024/06/01) ♡
• Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy. (2024/06/01) ♡
• Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib. (2024/05/22) ♡
• Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway. (2024/05/01) ♡
• Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. (2024/04/15) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Bilateral, sequential orbital inflammatory syndrome associated with ruxolitinib. (2024/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Glucose-6-phosphate dehydrogenase deficiency with coinherited Gaucher disease: A rare association. (2024/04/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults. (2024/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Momelotinib in myelofibrosis. (2024/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. An Elusive Diagnosis of Castleman Disease. (2024/03/27) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3. (2024/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera. (2024/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient. (2024/03/01) ♡
• Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. (2024/03/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Overt primary myelofibrosis with coexistence of JAK2V617F and MPLW515R driver mutations. (2024/02/01) ♡
• Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes. (2024/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia. (2024/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. (2024/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT. (2024/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis. (2024/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Pathergy in a patient with pyoderma gangrenosum. (2024/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination. (2024/01/12) ♡
• A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia. (2024/01/04) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. CALR mutations possess unique prognostic relevance in myelofibrosis-before and after transplant. (2024/01/01) ♡
• The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. (2024/01/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. (2024/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Natural history of Ras-associated autoimmune leukoproliferative disorder: A 20-year follow-up of a NRAS-mutated patient excluding a malignant progression. (2024/01/01) ♡
• Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline. (2024/01/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.